SHENGDA BIO-PHARM(SH:603079) Shang Hai Zheng Quan Bao·2025-10-09 19:02Core Viewpoint - Zhejiang Sandar Biopharmaceutical Co., Ltd. is set to hold a Q3 2025 earnings presentation on November 5, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Earnings Presentation Details - The earnings presentation will take place on November 5, 2025, from 10:00 to 11:00 AM [5]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from October 29, 2025, to November 4, 2025, before 4:00 PM through the Roadshow Center website or via the company's email [2][4]. Group 2: Financial Management - The company approved the use of up to RMB 230 million of temporarily idle raised funds for cash management, focusing on safe and liquid financial products with a maturity of no more than 12 months [7]. - On August 29, 2025, the company purchased RMB 80 million in structured deposits from China Construction Bank, which matured on September 30, 2025, returning the principal and a yield of RMB 12.34 thousand [8]. Group 3: Employee Stock Ownership Plan - The first meeting of the 2024 Employee Stock Ownership Plan was held on October 9, 2025, with full attendance from the holders representing 100% of the plan's shares [9][10]. - A management committee was established to oversee the daily management of the employee stock ownership plan, consisting of three members [11]. - The committee was authorized to handle various responsibilities related to the employee stock ownership plan, including convening meetings and managing shareholder rights [12][13][14].